Abstract
Get full access to this article
View all access options for this article.
References
1.Information on biosimilars . https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/. Updated May 10 , 2016 . Accessed July 26, 2017 .
2.
Olech
E.
Biosimilars: rationale and current regulatory landscape . Semin Arthritis Rheum . 2016 ;45 (5 )(suppl ):S1 -S10 .
3.From our perspective: interchangeable biological products . https://www.fda.gov/Drugs/NewsEvents/ucm536528.htm. Updated July 18 , 2017 . Accessed July 26, 2017 .
4.Purple book: lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations . https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm411418.htm. Updated July 21 , 2017 . Accessed July 26, 2017 .
5.State laws and legislation related to biologic medications and substitution of biosimilars . http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx. Updated July 1 , 2017 . Accessed July 26, 2017 .